Brookline Capital Management Forecasts QNCX Q2 Earnings

Quince Therapeutics, Inc. (NASDAQ:QNCX) – Brookline Capital Management cut their Q2 2025 EPS estimates for Quince Therapeutics in a research report issued on Tuesday, May 13th. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings of ($0.29) per share for the quarter, down from their prior estimate of ($0.24). The consensus estimate for Quince Therapeutics’ current full-year earnings is ($1.21) per share. Brookline Capital Management also issued estimates for Quince Therapeutics’ Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.07) EPS, FY2026 earnings at ($0.82) EPS, FY2027 earnings at ($0.49) EPS, FY2028 earnings at $0.08 EPS and FY2029 earnings at $0.46 EPS.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10).

Several other analysts have also issued reports on QNCX. Oppenheimer began coverage on shares of Quince Therapeutics in a research report on Monday, March 24th. They set an “outperform” rating and a $10.00 price target on the stock. D. Boral Capital dropped their price target on shares of Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Quince Therapeutics currently has an average rating of “Buy” and an average target price of $8.00.

Quince Therapeutics Stock Performance

Shares of QNCX stock opened at $0.85 on Friday. The company’s fifty day simple moving average is $1.15 and its 200-day simple moving average is $1.51. The company has a quick ratio of 9.53, a current ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm has a market cap of $37.50 million, a PE ratio of -0.69 and a beta of 0.83. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45.

Institutional Trading of Quince Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Virtu Financial LLC lifted its stake in shares of Quince Therapeutics by 48.4% during the 1st quarter. Virtu Financial LLC now owns 43,332 shares of the company’s stock worth $58,000 after buying an additional 14,128 shares during the last quarter. Northern Trust Corp increased its position in Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock worth $94,000 after acquiring an additional 16,501 shares during the period. Anfield Capital Management LLC bought a new position in Quince Therapeutics during the fourth quarter worth about $50,000. Two Sigma Investments LP bought a new position in Quince Therapeutics during the fourth quarter worth about $57,000. Finally, Geode Capital Management LLC increased its position in Quince Therapeutics by 10.9% during the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after acquiring an additional 36,807 shares during the period. Institutional investors and hedge funds own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.